INCA32459
- Generic Name
- INCA32459
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT05577182
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University of Texas Md Anderson Cancer Center, Houston, Texas, United States
🇧🇪Cliniques Universitaires Ucl Saint-Luc, Bruxelles, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath